Editorial S1 Context and cooperation S3 Responsibility S4 Composition of the Guideline Group S4 Autonomy S4 Aims and method S4 Multimedication guideline S5 Summary S6 Prescription process S6 General measures for reducing undesirable multimedication S7 Multimedication guideline S8 Aims and target groups of the guidelines S8 Explanation S8 Key questions for general practitioners This journal is included in the abstracting and indexing coverage of the Bio-Sciences Information Service of Biological Abstracts, and is listed in Current Contents (Life Sciences), MEDLINE, International Pharmaceutical Abstracts, EMBASE/Excerpta Medica, Elsevier BIOBASE/Current Awareness in Biological Sciences, SCOPUS. All articles published in the International Journal of Clinical Pharmacology and Therapeutics must be contributed to it exclusively. The following types of papers are acceptable: original papers, outline summaries of special problems, letters to the editor, short news items on new developments and other topics of current interest. All experimental data should be obtained from humans. Animal and in vitro investigations can be published only occasionally and only on condition that they have a close relationship to human pharmacological investigations. The editor responsible reserves the right of selection from submitted manuscripts (after consulting at least two reviewers) and the right to make stylistic changes or abridgements. The manuscripts may not be submitted elsewhere for printing or publication; following acceptance the publisher acquires all copyrights.

In December 2017, the National Academy of Neuropsychology convened an interorganizational Summit on Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients in Denver, Colorado. The Summit brought together representatives of a broad range of stakeholders invested in the care of older adults to focus on the topic of cognitive health and aging. Summit participants specifically examined questions of who should be screened for cognitive impairment and how they should be screened in medical settings. This is important in the context of an acute illness given that the presence of cognitive impairment can have significant implications for care and for the management of concomitant diseases as well as pose a major risk factor for dementia. Participants arrived at general principles to guide future screening approaches in medical populations and identified knowledge gaps to direct future research. Key learning points of the summit included: recognizing the importance of educating patients and healthcare providers about the value of assessing current and baseline cognition;emphasizing that any screening tool must be appropriately normalized and validated in the population in which it is used to obtain accurate information, including considerations of language, cultural factors, and education; andrecognizing the great potential, with appropriate caveats, of electronic health records to augment cognitive screening and tracking of changes in cognitive health over time. Summit Participants Deb Adler1, Christopher Alban, MD, MBA2, Mark Bondi, PhD3, Michelle Braun, PhD4, Xavier Cagigas, PhD5, Morgan Daven6, Robert L. Denney, PsyD7,8, Lisa Drozdick, PhD9, Norman L. Foster, MD10,11, Ula Hwang, MD12–15, Laurie Ivey, PsyD16, Grant Iverson, PhD7,17, Joel Kramer, PsyD18, Laura Lacritz, PhD7,19, Melinda Lantz, MD20, Lisa Latts, MD, MSPH, MBA21, Shari M. Ling, MD22, Ana Maria Lopez, MD23–26, Michael Malone, MD27,28, Lori Martin-Plank, PhD, MSN, MSPH, RN29, Katie Maslow, MSW30, Don Melady, MSc(Ed), MD31–33, Melissa Messer34, John Meyers, PsyD7, Charles E. McConnel, PhD19, Randi Most, PhD36, Margaret P. Norris, PhD37, William Perry, PhD7,85,39, Neil Pliskin, PhD40, David Shafer, MBA41, Nina Silverberg, PhD42, Tresa Roebuck-Spencer, PhD43,44, Colin M. Thomas, MD, MPH45, Laura Thornhill, JD46, Jean Tsai, MD, PhD10,47, Nirav Vakharia, MD48, Martin Waters, MSW49 Organizations Represented Alzheimer’s Association, Chicago, ILAMA/CPT Health Care Professionals Advisory Committee, Chicago, ILAmerican Academy of Clinical Neuropsychology (AACN), Ann Arbor, MIAmerican Academy of Neurology (AAN), Minneapolis, MNAmerican Association of Geriatric Psychiatry (AAGP), McLean, VAAmerican Association of Nurse Practitioners (AANP), Austin, TXAmerican Board of Professional Neuropsychology (ABN), Sarasota, FLAmerican College of Emergency Physicians (ACEP), Philadelphia, PAAmerican College of Physicians (ACP), Philadelphia, PAAmerican Geriatrics Society (AGS), New York, NYAmerican Psychological Association (APA), Washington,...

In December 2017, the National Academy of Neuropsychology convened an interorganizational Summit on Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients in Denver, Colorado. The Summit brought together representatives of a broad range of stakeholders invested in the care of older adults to focus on the topic of cognitive health and aging. Summit participants specifically examined questions of who should be screened for cognitive impairment and how they should be screened in medical settings. This is important in the context of an acute illness given that the presence of cognitive impairment can have significant implications for care and for the management of concomitant diseases as well as pose a major risk factor for dementia. Participants arrived at general principles to guide future screening approaches in medical populations and identified knowledge gaps to direct future research. Key learning points of the summit included: recognizing the importance of educating patients and healthcare providers about the value of assessing current and baseline cognition;emphasizing that any screening tool must be appropriately normalized and validated in the population in which it is used to obtain accurate information, including considerations of language, cultural factors, and education; andrecognizing the great potential, with appropriate caveats, of electronic health records to augment cognitive screening and tracking of changes in cognitive health over time.

Colorado. The Summit brought together representatives of a broad range of stakeholders invested in the care of older adults to focus on the topic of cognitive health and aging. Summit participants specifically examined questions of who should be screened for cognitive impairment and how they should be screened in medical settings. This is important in the context of an acute illness given that the presence of cognitive impairment can have significant implications for care and for the management of concomitant diseases as well as pose a major risk factor for dementia. Participants arrived at general principles to guide future screening approaches in medical populations and identified knowledge gaps to direct future research. Key learning points of the summit included: recognizing the importance of educating patients and healthcare providers about the value of assessing current and baseline cognition; emphasizing that any screening tool must be appropriately normalized and validated in the population in which it is used to obtain accurate information, including considerations of language, cultural factors, and education; and recognizing the great potential, with appropriate caveats, of electronic health records to augment cognitive screening and tracking of changes in cognitive health over time.

No abstract